Abbott’s device will join the Dexcom G5 as the only continuous glucose monitoring systems covered under the federal program.
Update: 7/28/2018 – Abbott announced yesterday that the FDA has now approved Freestyle Libre Flash System sensors that users will be able to wear for up to 14 days. The sensors will also have a reduced warm-up time. You can read more about the announcement here: http://abbott.mediaroom.com/2018-07-27-Abbotts-FreeStyle-R-Libre-14-Day-Flash-Glucose-Monitoring-System-Now-Approved-in-U-S
On January 4th, 2018, Abbott Laboratories announced it had received word that its FreeStyle Libre System will be covered by Medicare. The Centers for Medicare and Medicaid Services (CMS) ruled that the new glucose monitoring system, which was approved by the FDA in 2017, met the standards for a “therapeutic CGM system,” according to a press release.
Want more type 1 diabetes-related news stories, and the chance to help type 1 diabetes research? Take a moment to join Glu now by clicking here: https://myglu.org/sign_up.
The FreeStyle Libre joins the Dexcom G5 as the only continuous glucose monitoring systems (CGMs) covered by Medicare. In order for a CGM to be eligible for CMS coverage under relatively new guidelines, the system must be designed in such a way that it does not require a separate fingerstick for calibration. The FreeStyle Libre is factory-calibrated, which eliminates the need for fingerstick recalibration, according to the press release. In the last several years, diabetes advocates had been pushing Medicare to provide coverage for CGMs, and this recent shift in federal policy has been seen as an important victory in the quest to expand access of diabetes care technology.
To learn more about the FreeStyle Libre, click here.
To learn more about the Dexcom G5, click here.
Glu is published by T1D Exchange, a non-profit dedicated to improving care and accelerating therapies for people affected by type 1 diabetes. If you would like to donate to our mission, please click here.